Vision-Sciences-Uroplasty merger, Gilead's Sovaldi & more – 7 GI company key notes

Here are seven recent news updates on gastroenterology and endoscopy companies.

Olympus received U.S. Food and Drug Administration clearance to introduce its Narrow Band Imaging technology in the United States.

Uroplasty and Vision-Sciences entered into a definitive merger agreement.

KARL STORZ Endoscopy-America's IMAGE 1 SPIES Visualization Enhancement Tools system was recognized as a 2014 Innovation of the Year by the Society of Laparoendoscopic Surgeons.

Express Scripts, one of the largest pharmacy benefit managers in the country, will cover AbbVie's new hepatitis C treatment and will no longer cover Gilead Sciences treatments.

Actavis appointed Jonathon Kellerman as executive vice president, global chief compliance officer. Additionally, Actavis President and CEO Brent Saunders will continue to lead the firm after its acquisition by Allergan in the second quarter of next year.

TiGenix submitted the required documentation for a Special Protocol Assessment of its pivotal Phase III trial design for Cx601 to the U.S. Food and Drug Administration.

The U.S. Food and Drug Administration approved AbbVie's Viekira Pak to treat patients with chronic hepatitis C virus, including those with cirrhosis.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Anuja Vaidya at avaidya@beckershealthcare.com.

More articles on GI/endoscopy:

Olympus receives FDA approval for Narrow Band Imaging technology
Is sending removed polyps for pathological examination still necessary? 5 things to know
Holzer Health System names gastroenterologist Dr. Christopher Meyer CEO

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast